G1 TherapeuticsNASDAQ: GTHX

G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Monday after the company provided investors with an update on its Phase 3 clinical trial of trilaciclib as a breast cancer treatment. G1 Therapeutics notes that this trial failed to meet its primary endpoint.

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negativ

RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial will be presented in a poster session during the upcoming 2024 American Society of Clinical Oncology (ASCO) Meeting.

G1 Therapeutics (GTHX) reported a quarterly loss of $0.20 per share, slightly below the Zacks Consensus Estimate of $0.19, compared to a loss of $0.53 per share in the same quarter last year.

G1 Therapeutics, Inc. (Nasdaq: GTHX) will hold a webcast and conference call on May 1, 2024, at 8:30 a.m. to discuss their financial and corporate update for the first quarter of 2024.

G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lung Cancer. The company's research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer, reporting a 29% increase in Cosela's net revenues in Q4 2023.

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.73 per share a year ago.

G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Tuesday after the biopharmaceutical company provided an interim update on a Phase 3 clinical trial of trilaciclib as a breast cancer treatment. This clinical trial has trilaciclib being used in combination with gemcitabine and carboplatin as a first line treatment for metastatic triple negative breast cancer (mTNBC).

G1 Therapeutics has provided pipeline updates, including encouraging preliminary overall survival data from a phase 2 study of trilaciclib in combination with sacituzumab govitecan for advanced triple-negative breast cancer. The company aims to pursue global partnerships for the release and support of trilaciclib if positive results are obtained from the ongoing trials. G1 Therapeutics' cash runway has been extended into early 2025, providing more time to address FDA filings and potential partnerships.